CDK4 and osteosarcoma: Although previous studies have indicated a potential prognostic value of CDK4 amplification or overexpression in several cancer types, including liposarcoma and osteosarcoma, as well as acral and mucosal melanoma [25–28], it has not been proven as an independent risk factor for melanoma prognosis [27, 28].